Editorial Commentary
Revisiting the role of neoadjuvant radiotherapy in stage III non-small cell lung cancer: insights from the SQUAT trial
Shanghai Chest
2026;
10:
19
.
(30 July 2026)
Editorial Commentary
Optimizing upfront combination therapy in advanced epidermal growth factor receptor mutation (EGFR)-mutated non-small cell lung cancer
Shanghai Chest
2026;
10:
18
.
(30 July 2026)
Editorial Commentary
Radiation in the setting of perioperative chemoimmunotherapy in resectable stage III NSCLC: not ready for prime time yet
Shanghai Chest
2026;
10:
17
.
(30 July 2026)
Editorial Commentary
More is not always better: lessons from the SQUAT trial (WJOG 12119L) in resectable-N2 non-small cell lung cancer
Shanghai Chest
2026;
10:
16
.
(30 July 2026)
Editorial Commentary
Which ablation, for which tumor, in which patient?—reconsidering radiofrequency ablation for stage I non-small cell lung cancer
Shanghai Chest
2026;
10:
15
.
(30 July 2026)